Clinical trials: Polymers
Coronary Artery Disease
Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent: A Optical Coherent Tomography Study
Our hypothesis is to test that 1) The safety and efficacy of Nano+ DES in patients with de novo lesions; 2) A low neointimal hyperplasia after Nano+ DES implantation due to its effective and sufficient antiproliferative drug; 3)…
- Trial name
- NCT01925027
- Testing
- Nano+ DES
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 45 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Coronaropathy
Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems
The TRANSLUMINA GmbH YuChooSeR Observatory is a prospective, multicentric post-marketing observatory designed to evaluate large scale safety and reliability of the Yukon Choice PC and the Yukon Chrome PC stents systems use in…
- Trial name
- YuChooSeR (NCT03918070)
- Testing
- Yukon Choice PC and Yukon Chrome PC
- Where
- 19 sites in France
- Volunteers
- 2,722 people
- Sponsor
- Translumina GmbH
Head and Neck Squamous Cell Carcinoma
Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC
A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or metastatic head and neck squamous cell carcinoma
- Trial name
- NCT02639858
- Testing
- Docetaxel-PM
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Infection, Post-operative Care
The Use of a Novel Microbicidal Liquid Polymer for the Reduction of Pin Track Infection
The purpose of the study is to investigate additional clinical uses for the polymer, which is a FDA approved, 510k, medical device, but has not been approved for use on patients with pin track sites as a way to lower the…
- Trial name
- NCT03756506
- Testing
- Novel Microbicidal Liquid Polymer
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Prevent-Plus LLC
Coronary Artery Disease
Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent
This is a prospective, multicenter, open-label, single-arm registry. The primary objective of this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer patients (800 patients as in the Supraflex…
- Trial name
- NCT04138238
- Testing
- Supraflex Cruz Sirolimus-eluting Stent
- Where
- 26 sites in France, Germany and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Sahajanand Medical Technologies Limited
Coronary Artery Disease
First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis
Prospective, multi-center, randomized 1:1, single blind trial using BuMA Supreme versus Resolute Integrity conducted in approximately 14 interventional cardiology centers in The Netherlands, Belgium, Spain and Portugal.
- Trial name
- NCT02236975
- Testing
- BuMA Supreme Biodegradable drug coating coronary stent system, Resolute Integrity durable polymer stent system
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 168 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Healthy
Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions
This study was designed to investigate the bioequivalence of the test and reference products when administered as single oral doses in two consecutive study periods, under fasting conditions.
- Trial name
- NCT05136521
- Testing
- Trazodone HCl - new polymer, Trazodone HCl - Contramid®
- Where
- Switzerland
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Coronary Artery Disease
Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent
The purpose of the EVOLVE Trial is to assess the safety and performance of the everolimus-eluting Evolution stent for the treatment of a de novo atherosclerotic lesion of up to 28 mm in length in a native coronary artery 2.25 mm…
- Trial name
- Evolve (NCT01135225)
- Testing
- PROMUS(TM) Element (TM) Stent System, Evolution Stent System
- Where
- 29 sites in Australia, Belgium and 7 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
Severe Mitral Valve Regurgitation, Severe Mitral Valve Stenosis
The Feasibility Study of Polymer Artificial Heart Valve for the Treatment the Mitral Valve Disease.
The study aims to evaluate the feasibility and safety of polymer artificial heart valve designed and developed by Shanghai HeartEpoch Medical technology Co. Ltd. for the treatment of the mitral valve diseases.
- Trial name
- HeartEpoch (NCT07243184)
- Testing
- mitral valve replacement
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai HeartEpoch Medical Technology Co., Ltd
Venous Leg Ulcer (VLU), Diabetic Foot Ulcer (DFU)
Effectiveness of Silicone Superabsorbent Polymer Dressings for Chronic Wound Management
The purpose of this single arm clinical study is to find out how well two Silicone superabsorbent polymer dressings, RespoSorb Silicone (also known as Zetuvit Plus Silicone) and RespoSorb Silicone Border (also known as Zetuvit…
- Trial name
- NCT07549737
- Testing
- RespoSorb Silicone (RSSil), RespoSorb Silicone Border (RSSB)
- Where
- 8 sites in Poland
- Volunteers
- 80 people
- Sponsor
- HARTMANN GROUP
Coronary Disease
Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis
The purpose of the study is to evaluate the effectively of coating of coronary stents with two different doses of rapamycin for the prevention of coronary vessel re-blockage
- Trial name
- NCT00152308
- Testing
- 2% rapamycin-eluting YUKONdes PEARL-stent, 1% rapamycin-eluting YUKONdes PEARL-stent
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 333 people
- Sponsor
- Translumina GmbH
Metastatic Breast Cancer, Stage IV Breast Cancer
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
The purpose of this study is to estimate the cumulative Maximum Tolerated Dose (MTD) and Minimum Efficient Dose (MED) of BP-C1 in the short-term treatment of metastatic breast cancer patients.
- Trial name
- NCT04298333
- Testing
- BP-C1
- Where
- 3 sites in Indonesia, Taiwan and 1 more
- Volunteers
- 18 people
- Sponsor
- Meabco A/S
Coronary Arteriosclerosis
Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions
To evaluate the safety, efficacy and deliverability of the Combo bio-engineered sirolimus-eluting stent versus the Nano polymer-free sirolimus- eluting stents in the treatment of patients with de novo stenotic lesions of native…
- Trial name
- RECOVERY (NCT02542007)
- Testing
- OrbusNeich Combo stent™, sirolimus-eluting stent system
- Where
- 15 sites in China
- Volunteers
- 440 people
- Sponsor
- OrbusNeich
Pulmonary Emphysema, COPD
AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema
The purpose of this study is to assess the procedural and post-procedural safety and efficacy of AeriSeal therapy at up to 4 subsegments during a single treatment session in patients with GOLD Stage III/IV homogeneous or…
- Conditions
- Pulmonary Emphysema, COPD, Lung Diseases
- Trial name
- NCT01181466
- Testing
- AeriSeal System
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Aeris Therapeutics
Hepatitis B, Chronic, Hepatitis D, Chronic
A Long Term Follow-up Study of Patients From the REP 301 Protocol
The REP 301 treatment protocol involved the treatment of patients with chronic hepatitis B / hepatitis D co-infection with two agents: REP 2139-Ca and pegylated interferon (peg-IFN).
- Trial name
- NCT02876419
- Where
- Moldova
- Volunteers
- 11 people
- Sponsor
- Replicor Inc.
Common Cold
A Study of an Experimental Nasal Spray in Subjects With Early Signs of the Common Cold
This study will test 200 people to see if an experimental nasal spray has an effect on symptoms of the common cold if used when the symptoms start.
- Trial name
- NCT01488604
- Testing
- Polymeric Nasal Spray
- Where
- 3 sites in United Kingdom
- Volunteers
- 163 people
- Sponsor
- McNeil AB
Coronary Artery Disease
Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial
The purpose of this study is to evaluate new generation drug eluting stent (DES) of MicroPort of its safety, efficacy and delivery system in treating CAD.
- Trial name
- NCT01196819
- Testing
- Firehawk, Xience V
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Bioavailability Heathy Volunteers, Bioavailability Study
Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state.
Two way, two parallel groups, crossover study to compare the bioavailability of 150 mg and 300 mg trazodone hydrochloride (new polymer) (Angelini Pharma S.p.A.) vs.
- Conditions
- Bioavailability Heathy Volunteers, Bioavailability Study, Bioequivalance
- Trial name
- NCT06773767
- Testing
- 150 mg trazodone hydrochloride, 300 mg trazodone hydrochloride
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Aortic Dissection
False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study (FLAGSHIP_CHL)
To determine the safety and feasibility of the investigational product to reduce aortic dissection false lumen perfusion.
- Trial name
- FLAGSHIP_CHL (NCT07387250)
- Testing
- False Lumen Embolization System, IMPEDE-FX RapidFill
- Volunteers
- 15 people
- Sponsor
- Shape Memory Medical, Inc.
HIV Infections, Gonorrhea
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
The objective of the study is to determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection.
- Conditions
- HIV Infections, Gonorrhea, Chlamydial Infections, Genital Herpes
- Trial name
- NCT00262106
- Testing
- PRO 2000/5
- Where
- 6 sites in South Africa, Tanzania and 2 more
- Volunteers
- 9,404 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company